Compare Cassava Sciences Inc (FLNA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tripadvisor Inc Common Stock — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Tripadvisor Inc Common Stock trades at $14.52 (market cap $1.70B). The key difference: Tripadvisor Inc Common Stock is far larger — about 32× Cassava Sciences Inc's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TRIP | |
|---|---|---|
Market Cap | $53.14M | $1.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $19.14 |
52-Week Low | $1.09 | $9.24 |
Enterprise Value | -$33.43M | $1.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Tripadvisor (TRIP) trades at $14.00, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but beat in Q3 2025, with revenue growing to $1.89B in 2025. Recent news highlights the $700M sale of TheFork to American Express, providing strategic focus and cash infusion.
Outlook remains cautious with analyst consensus at Hold (60.72%) and price target of $13.87 below current price. Key risks include competitive pressures and macroeconomic headwinds, while opportunities lie in travel recovery and TheFork sale proceeds. The stock faces near-term pressure but has long-term potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
